NECLIFE · Health Care · 2026-08-07

Nectar Lifesciences Ltd

Stage 4 · wk 4In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹10.6
+0.76% today
₹206 Cr · Micro cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

Visit company website →
Earnings Growth (YoY)
+82.9%
Revenue —
vs 52W High
-52.4%
₹9.3 lo₹22.3 hi
52.4% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 4
1w13w26w
Week 4 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-22.2%
200 DMA: ₹13.6 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.64x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -4.6% vs MA50 -6.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Industry has 53 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S2 18w
S3 16w
S4 39w
S4 15w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 3w → S1 8w → S2 12w → S3 5w → S2 18w → S3 16w → S4 5w → S1 1w → S2 10w → S3 7w → S2 6w → S3 1w → S4 39w → S1 10w → S4 15w → S1 7w → S4 3w current
Total tracked: 168 weeks across 17 stage runs.
1M
-5.8%
3M
-26.3%
6M
-23.7%
YTD
-44.6%
1Y
-36.3%
Scan Membership
Breakout Watch
Latest: 2025-01-07
2 appearances in last 60 days. First seen: 2024-09-09.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S4
Wk 4 · Vol —x
2026-08-06S4
Wk 4 · Vol —x
2026-08-05S4
Wk 4 · Vol —x
2026-08-04S4
Wk 3 · Vol —x
2026-08-03S4
Wk 3 · Vol —x
2026-07-31S4
Wk 3 · Vol —x
2026-07-30S4
Wk 3 · Vol —x
2026-07-29S4
Wk 3 · Vol —x
2026-07-28S4
Wk 2 · Vol —x
2026-07-27S4
Wk 2 · Vol —x
2026-07-24S4
Wk 2 · Vol —x
2026-07-23S4
Wk 2 · Vol —x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹11.3
200 DMA
₹13.6
52W High
₹22.3
52W Low
₹9.3
5D Low
₹10.5
Resistance levels (recent highs)
20d High
₹11.2
60d High
₹12.8
120d High
₹14.4
250d High
₹22.3
Next resistance
+5.8%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.